headshot 2016

[accordion-item title=”STEVE MAYLISH | CCO | FUSION BIOTEC” state=closed]

Steve Maylish has been a part of the medical device community for more than thirty years. Currently he is the chief commercial officer for Fusion Biotec, a contract engineering firm in Irvine, California serving the medical device community. Early in his career, Mr. Maylish held positions at Fortune 100 corporations such as Johnson & Johnson, Shiley, Sorin Group, Baxter Healthcare and Edwards Lifesciences. After receiving his MBA in 2002, Mr. Maylish focused his business development talents on two boutique medical design and manufacturing firms, both of which successfully exited through acquisition. Afterward, he founded Maytrix Medical to provide business development to third-party engineering firms. Mr. Maylish has an A.S. degree in Electronics from RETS Electronics Institute, a B.S. in Business from the University of La Verne and an MBA from the University of California, Irvine.

Park 008 websize

[accordion-item title=”CURTIS PARK | CFO | ENTREPRENEURS WITHOUT BORDERS” state=closed]

Since 1981 Curtis has been a founder, key management team member, and investor in numerous entrepreneurial companies including oil and gas exploration, commercial real estate development, manufacturing, professional practices, R&D defense contracting, and others. Starting from virtually zero in 1981, Curtis and his key partners grew a family of companies to an estimated market value of well over $100 million by 1987.

Beginning in 2006, Curtis became Chief Financial Officer and a Director of the California Coast Venture Forum. At that time, he began to redirect his efforts to mentoring other entrepreneurs and helping them network with investors, key management talent, strategic partnering relationships, and service providers. By 2014, substantially all of his efforts were devoted to the volunteer mentoring and networking activities of the California Coast Venture Forum.

click here to learn more …

ASHOT 2015 (3)


Dr. Ashot Petrossian has more than 30 years experience in the biopharmaceutical and biotechnology industry in the various areas of product and process development for proteins, peptides, and large molecules. Ashot’s core expertise is large-scale GMP cell and microbial culture fermentation using production-scale bioreactors, purification unit operations using tangential flow and large-scale chromatography systems and final product presentation. Ashot has expertise with the conceptual design and construction of GMP facilities for the production of biopharmaceuticals and all aspects of the facility, equipment, process, cleaning and analytical methods validation. Ashot held positions in operations and compliance at numerous biopharmaceutical and consulting companies.

Dr. Ashot Petrossian earned a B.S. degree in Biochemistry from Cornell and a Ph.D. degree in Biophysics from University of California at Berkeley.


[accordion-item title=”MICHAEL REILLY | CEO & CO-FOUNDER | EXCELSE BIO” state=closed]

Michael J. Reilly is the CEO and Co-Founder of Excelse Bio based in Thousand Oaks, a privately held firm transforming intravenous biologics into small subcutaneous doses. He has been working in biotechnology for 30 years at Amgen, Baxter, Sanofi, Sterling Drug, and several startups. Michael earned a Master’s degree from the Ross School of Business at the University of Michigan in Ann Arbor, and a Bachelor’s degree in Molecular Biology from the University of California, Berkeley.

Villalta-Josue-HI 2015-08-01

[accordion-item title=”JOSUE VILLATA | PARTNER | KNOBBE MARTENS” state=closed]

Josue Villalta is a partner in the Los Angeles office of Knobbe Martens Olson & Bear, LLP.  Mr. Villalta specializes in patent protection, including patent prosecution, patent portfolio management, IP due diligence and general counseling on infringement issues.  Mr. Villalta represents clients in a wide range of technologies including medical devices.  In the medical device field, Mr. Villalta represents clients in surgical robotic devices, orthopedic devices, prosthetics, and ophthalmic devices, among others.


[accordion-item title=”STEPHEN WILLIAM | PARTNERS | CATALYST ADVISORS LP” state=closed]

Steve Williams is a Partner with Catalyst Advisors, LP, a retained executive recruiting firm serving life science companies exclusively, having offices in New York, London and Los Angeles.  Prior to joining Catalyst Advisors, Steve served as the president and chief business officer of another global life sciences recruiting firm. Before his recruiting career, Steve held a range of roles at both pharmaceutical and biotechnology companies.  Steve began his career as a research toxicologist at DuPont and then led the discovery and pre-clinical development of Cardiolite® and Neurolite® at DuPont and DuPont Merck Pharmaceuticals. He also has held leadership positions in line marketing, strategic product planning, and business development. He was a medical director in new product planning at Bristol-Myers Squibb and was a key member of the management team that executed a successful IPO at Progenitor, a biotechnology company. Steve received his B.S. in biology from the University of North Carolina at Chapel Hill and his Ph.D. in pharmacology from Duke University.


[accordion-item id=”item-4″ title=”MICHAEL J. WISE | PARTNER | PERKINS COIE” state=closed]

Michael Wise, a partner with Perkins Coie, is the firmwide co-chair of the Life Sciences practice and the Regional Managing Partner for China.  Recognized by Chambers Global as a ‘Leading Lawyer’ and by Intellectual Asset Management in the IAM Patent 1000, Michael’s practice primarily focuses on patent litigation, post-grant proceedings, patent prosecution, ITC Section 337 actions, global patent portfolio management, patent landscape assessments, freedom to operate and patent due diligence.  He has litigated a wide variety of technologies, including biologic and small molecule therapeutics, diagnostics, medical devices, software, and electronics.  For the last 15 years, Michael has been an active member of the Southern California Biomedical Council (SoCalBio); he has served as the chair of the annual SoCalBio Investor Conference and is the secretary of the Board of Directors.  He also regularly advises academic institutions, research institutions, emerging companies, privately held companies and publicly traded companies with respect to protecting and enforcing their intellectual property rights.



Pages: 1 2